title: Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra.
authors: Paediatric Rheumatology, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7HE, UK. nick.wilkinson@ouh.nhs.uk.
authors: Sarah M
authors: SM
authors: Keidel
authors: Rachel K
authors: RK
authors: Hoyles
authors: Nick M R
authors: NM
authors: Wilkinson
mesh_terms: D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015897:Comorbidity; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000453:epidemiology; D014657:Vasculitis / Q000188:drug therapy* / Q000453:epidemiology; D000093242:Interleukin-6 Inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053590:Interleukin 1 Receptor Antagonist Protein; D000093242:Interleukin-6 Inhibitors; C502936:tocilizumab